Total (N = 185) | Incident RA (N = 46) | Prevalent RA (N = 139) | P value | |
---|---|---|---|---|
Female (%) | 76.8 | 69.6 | 79.1 | 0.066 |
Age (years) | 55.2 (14.0) | 51.7 (12.6) | 56.4 (14.2) | <0.001* |
Disease duration (years) | 6.3 (7.7) | 0.8 (0.7) | 8.1 (8.1) | <0.001* |
Symptom duration (years) | 7.3 (7.7) | 1.5 (1.8) | 9.2 (8.0) | <0.001* |
BMI | 26.7 (4.5) | 27.5 (5.2) | 26.4 (4.3) | 0.020* |
RF+ (%) | 47.2 | 43.5 | 48.5 | 0.466 |
ACPA+ (%) | 62.9 | 58.7 | 64.3 | 0.952 |
CRP (mg/l) | 7.6 (9.0) | 10.5 (12.6) | 6.6 (7.1) | 0.354 |
DAS28-CRP | 3.7 (1.5) | 4.0 (1.5) | 3.6 (1.5) | 0.192 |
GSsynSS | 6.91 (6.39) | 7.70 (5.62) | 6.65 (6.61) | 0.255 |
PDsynSS | 4.02 (5.20) | 5.24 (5.95) | 3.61 (4.87) | 0.438 |
GStenSS | 0.66 (1.15) | 0.78 (1.18) | 0.63 (1.14) | 0.842 |
PDtenSS | 0.68 (1.63) | 0.80 (1.75) | 0.63 (1.59) | 0.402 |
Erosions score | 1.18 (2.10) | 0.46 (1.50) | 1.42 (2.21) | <0.001* |
HAQ | 0.77 (0.73) | 0.88 (0.73) | 0.74 (0.73) | 0.896 |
Oral glucocorticoids (%) | 43.8 | 41.3 | 44.6 | 0.607 |
csDMARDs (%) | 87.0 | 69.6 | 92.8 | <0.001* |